Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Benchtop Hematology Analyzer Enables Reduction of Manual Review Rates and Processes

By BiotechDaily International staff writers
Posted on 09 May 2013
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
A new benchtop hematology cellular analysis system provides laboratories with quality results, improved first-pass accuracy, and automatic rerun and reflex testing, thereby reducing overall manual review rates and processes.

Building on its proven cellular analysis technology to further advance and optimize clinical diagnostic laboratories, Beckman Coulter Inc. (Pasadena, CA, USA) introduces the “UniCel DxH 600” Coulter cellular analysis system, a new benchtop hematology analyzer for mid- to high-volume laboratories. The hematology laboratory’s single most important step, and most time consuming, is the manual review. By reducing manual differential rates, the new analyzer frees labs to focus time on quickly and accurately reporting patient results, improving patient health, and reducing the overall cost of care.

With the same technology, user interface, and consumables as the UniCel DxH 800 Coulter analyzer, the UniCel DxH 600 brings superior standardization of results and process to the hematology laboratory, reducing personnel training and simplifying consumable inventory management. (To further enhance standardization, all new DxH 800 analyzers will be installed with the advanced software; and DxH 800 currently in use will be upgraded.)

The UniCel DxH 600 is equipped with robust software—recently cleared by the US Food and Drug Administration (FDA)—that provides new features, enhancements, and research-use parameters. This advanced software also saves time by allowing labs to partially release patient results manually or automatically via decision rules. It also offers users the ability to create and edit decision rules during instrument operation and offers predefined decision rules using Cell Population Data (for research use only; not for use in diagnostic procedures). Additional features include the ability to track workload by the day, hour, and test, as well as providing automatic notification of STAT samples that have not been processed or released within an expected time frame, helping users to report STAT results efficiently.

"This new hematology analyzer has the ability to transform the hematology lab with unparalleled efficiency, revolutionary scalability, and quality of results,” said John Blackwood, senior vice president, Product Management at Beckman Coulter Diagnostics; “The UniCel DxH 600 advances the technology that [...] will change how labs manage their cellular analysis process.”

Related Links:

Beckman Coulter




comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.